Search
BMY.US: No Accelerated pathway does not imply registrational failure
- Amit Roy
- Jan 20, 2017
- 1 min read
Bristol's announcement that it is not pursuing an accelerated FDA approval pathway for Yervoy and Opdivo in first line lung cancer was predictable
Comments